Gregory G Schwartz

List of Publications by Year in Descending Order

82 papers	9,215 citations	38 h-index	90 g-index
90 ext. papers	11,356 ext. citations	11.3 avg, IF	5.47 L-index

#	Paper	IF	Citations
82	Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial.. *Lancet Diabetes and Endocrinology,the*, **2022**,	18.1	4
81	Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial.. *Circulation Genomic and Precision Medicine*, **2022**, 101161CIRCGEN121003503	5.2	0
80	Existing and emerging strategies to lower Lipoprotein(a). *Atherosclerosis*, **2022**, 349, 110-122	3.1	9
79	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. *Diabetes Care*, **2021**, 44, 1219-1227	14.6	9
78	Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. *Journal of the American College of Cardiology*, **2021**, 77, 1182-1193	15.1	31
77	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. *Circulation*, **2021**, 143, 1109-1122	16.7	16
76	Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial. *Clinical Journal of the American Society of Nephrology: CJASN*, **2021**, 16, 705-716	6.9	14
75	Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. *Cardiovascular Diabetology*, **2021**, 20, 125	8.7	2
74	Myocardial Infarction and Evolocumab. *JAMA Cardiology*, **2021**, 6, 1220-1221	16.2	1
73	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. *European Journal of Preventive Cardiology*, **2021**, 28, 33-43	3.9	10
72	Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. *Journal of Alzheimers Disease*, **2021**, 83, 1703-1715	4.3	3
71	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. *Journal of the American College of Cardiology*, **2021**, 78, 421-433	15.1	13
70	Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. *Cardiovascular Diabetology*, **2021**, 20, 13	8.7	17
69	Alirocumab after acute coronary syndrome in patients with a history of heart failure.. *European Heart Journal*, **2021**,	9.5	4
68	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. *Journal of the American College of Cardiology*, **2020**, 75, 2297-2308	15.1	23
67	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. *Circulation*, **2020**, 141, 1608-1617	16.7	52
66	Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2020**, 323, 1565-1573	27.4	57

65	Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. *Diabetes Care*, **2020**, 43, 1077-1084	14.6	13
64	Response by Schwartz et al to Letter Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial". *Circulation*, **2020**, 142, e335-e336	16.7	1
63	Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial. *Circulation*, **2020**, 141, 624-636	16.7	66
62	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. *Journal of the American College of Cardiology*, **2020**, 75, 133-144	15.1	147
61	Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. *American Heart Journal*, **2020**, 221, 60-66	4.9	3
60	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. *European Heart Journal*, **2020**, 41, 2248-2258	9.5	29
59	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. *European Heart Journal*, **2020**, 41, 4245-4255	9.5	44
58	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. *European Heart Journal*, **2020**, 41, 4114-4123	9.5	12
57	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. *Journal of the American College of Cardiology*, **2019**, 74, 1177-1186	15.1	33
56	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. *Circulation*, **2019**, 140, 1578-1589	16.7	24
55	Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. *Atherosclerosis*, **2019**, 290, 59-65	3.1	19
54	Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. *American Heart Journal*, **2019**, 217, 72-83	4.9	27
53	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. *European Heart Journal*, **2019**, 40, 2801-2809	9.5	27
52	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. *Circulation*, **2019**, 140, 103-112	16.7	72
51	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. *Journal of the American College of Cardiology*, **2019**, 74, 1167-1176	15.1	87
50	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 618-628	18.1	120
49	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. *Circulation: Cardiovascular Quality and Outcomes*, **2019**, 12, e005858	5.8	13
48	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. *Circulation*, **2019**, 140, 2054-2062	16.7	41

47	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. *Journal of the American College of Cardiology*, **2019**, 73, 387-396	15.1	96
46	Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. *Diabetes and Vascular Disease Research*, **2018**, 15, 14-23	3.3	11
45	Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. *JAMA Cardiology*, **2018**, 3, 164-168	16.2	51
44	Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease. *American Journal of Cardiovascular Drugs*, **2018**, 18, 109-115	4	70
43	Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial. *JAMA Cardiology*, **2018**, 3, 815-822	16.2	87
42	Preoperative Use of Statins in Carotid Artery Stenting: A Systematic Review and Meta-analysis. *Journal of Endovascular Therapy*, **2018**, 25, 624-631	2.5	4
41	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. *New England Journal of Medicine*, **2018**, 379, 2097-2107	59.2	1277
40	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. *Lancet, The*, **2018**, 392, 1311-1320	40	208
39	Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. *Journal of the American Heart Association*, **2017**, 6,	6	2
38	Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus. *Circulation*, **2017**, 135, 1882-1893	16.7	42
37	Metformin prevents ischaemic ventricular fibrillation in metabolically normal pigs. *Diabetologia*, **2017**, 60, 1550-1558	10.3	12
36	Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. *Cardiovascular Diagnosis and Therapy*, **2017**, 7, 45-51	2.6	35
35	Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. *Cardiovascular Drugs and Therapy*, **2017**, 31, 445-458	3.9	6
34	Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes. *Circulation: Cardiovascular Genetics*, **2016**, 9, 340-8		47
33	Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. *Journal of the American College of Cardiology*, **2016**, 68, 2488-2490	15.1	4
32	Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. *New England Journal of Medicine*, **2016**, 374, 1321-31	59.2	654
31	Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein. *Cardiovascular Drugs and Therapy*, **2015**, 29, 7-14	3.9	50
30	Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. *American Heart Journal*, **2015**, 170, 117-22	4.9	25

29	Adenylyl Cyclase 9 Polymorphisms Reveal Potential Link to HDL Function and Cardiovascular Events in Multiple Pathologies: Potential Implications in Sickle Cell Disease. *Cardiovascular Drugs and Therapy*, **2015**, 29, 563-572	3.9	2
28	Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. *Journal of the American College of Cardiology*, **2015**, 65, 2267-75	15.1	154
27	Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. *Circulation: Cardiovascular Genetics*, **2015**, 8, 372-82		119
26	Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. *JAMA - Journal of the American Medical Association*, **2014**, 311, 252-62	27.4	205
25	Evolving targets for lipid-modifying therapy. *EMBO Molecular Medicine*, **2014**, 6, 1215-30	12	6
24	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. *American Heart Journal*, **2014**, 168, 682-9	4.9	303
23	Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. *JAMA - Journal of the American Medical Association*, **2014**, 311, 1515-25	27.4	177
22	PCSK9 Inhibitors: potential in cardiovascular therapeutics. *Current Cardiology Reports*, **2013**, 15, 345	4.2	27
21	Dalcetrapib in patients with an acute coronary syndrome. *New England Journal of Medicine*, **2013**, 368, 869-70	59.2	10
20	Impaired contractile recovery after low-flow myocardial ischemia in a porcine model of metabolic syndrome. *American Journal of Physiology - Heart and Circulatory Physiology*, **2013**, 304, H861-73	5.2	8
19	New horizons for cholesterol ester transfer protein inhibitors. *Current Atherosclerosis Reports*, **2012** , 14, 41-8	6	13
18	Effects of dalcetrapib in patients with a recent acute coronary syndrome. *New England Journal of Medicine*, **2012**, 367, 2089-99	59.2	1424
17	PPAR-as a therapeutic target in cardiovascular disease: evidence and uncertainty. *Journal of Lipid Research*, **2012**, 53, 1738-54	6.3	46
16	Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs. *Cardiovascular Drugs and Therapy*, **2012**, 26, 195-204	3.9	11
15	High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. *American Heart Journal*, **2011**, 161, 993-9	4.9	26
14	High-density lipoprotein cholesterol as a risk factor and target of therapy after acute coronary syndrome. *American Journal of Cardiology*, **2009**, 104, 46E-51E	3	9
13	Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. *American Heart Journal*, **2009**, 158, 896-901.e3	4.9	166
12	Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study). *American Journal of Cardiology*, **2007**, 99, 632-5	3	49

11	Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. *JAMA - Journal of the American Medical Association*, **2006**, 295, 2046-56	27.4	119
10	PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs. *American Journal of Physiology - Heart and Circulatory Physiology*, **2005**, 288, H1314-23	5.2	45
9	Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. *Diabetes Care*, **2005**, 28, 2508-13	14.6	54
8	High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. *European Heart Journal*, **2005**, 26, 890-6	9.5	150
7	Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. *American Heart Journal*, **2004**, 148, e4	4.9	38
6	High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. *Circulation*, **2003**, 108, 1560-6	16.7	330
5	Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. *Circulation*, **2002**, 106, 1690-5	16.7	156
4	Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2001**, 285, 1711-8	27.4	1718
3	Non-elastic deformation of myocardium in low-flow ischemia and reperfusion: ultrastructure-function relations. *Journal of Molecular and Cellular Cardiology*, **1999**, 31, 1157-69	5.8	16
2	Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. *American Journal of Cardiology*, **1998**, 81, 578-81	3	65
1	Metabolic response of the human heart to inotropic stimulation: in vivo phosphorus-31 studies of normal and cardiomyopathic myocardium. *Magnetic Resonance in Medicine*, **1992**, 25, 260-72	4.4	42